Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • Merck
  • Merck Sharp and Dohme United Kingdom

This publication has 25 references indexed in Scilit: